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Abstract
Intermittent preventive treatment of malaria during pregnancy (IPTp) and insecticide-treated nets 
(ITN) are recommended malaria interventions during pregnancy; however, there is limited 
information on their efficacy in areas of low malaria transmission in sub-Saharan Africa.
An individually-randomised placebo-controlled trial involving 5775 women of all parities 
examined the effect of IPTp, ITNs alone or ITNs used in combination with IPTp on maternal 
anaemia and low birth weight (LBW) in a highland area of southwestern Uganda. The overall 
prevalence of malaria infection, maternal anaemia and LBW was 15.0%, 14.7% and 6.5%, 
respectively. Maternal and foetal outcomes were generally remarkably similar across all 
intervention groups (p>0.05 for all outcomes examined). A marginal difference in maternal Hb 
was observed in the dual intervention group (12.57 g/dL) compared with the IPTp and ITN alone 
groups (12.40 g/dL and 12.44 g/dL respectively; p=0.04), but this was too slight to be of clinical 
importance.
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In conclusion, none of the preventive strategies was found to be superior to the others, and no 
substantial additional benefit to providing both IPTp and ITNs during routine antenatal services 
was observed. With ITNs offering a number of advantages over IPTp, yet showing comparable 
efficacy, we discuss why ITNs could be an appropriate preventive strategy for malaria control 
during pregnancy in areas of low and unstable transmission.
Trial Registration: www.ClinicalTrials.gov NCT0042207
Keywords
malaria prevention; pregnancy; intermittent preventive treatment; insecticide-treated nets; low 
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Introduction
Malaria in pregnancy remains a major public health problem in sub-Saharan Africa. It is 
associated with low birth weight (LBW), intrauterine growth retardation and maternal 
anaemia.1-5 In addition to anaemia, malaria may contribute to maternal mortality by 
increasing the risk and severity of obstetric conditions such as pre-eclampsia/eclampsia and 
postpartum haemorrhage.6 In areas of low transmission, where women have little acquired 
immunity, malaria infections in pregnancy are more likely to give rise to clinical symptoms 
and may result directly in the loss of the foetus and/or maternal death.7,8 Malaria is also 
associated with an increased risk of stillbirth, with a seasonal pattern of higher incidence of 
stillbirths after peaks in rainfall.9 Dramatic increases in the risk of stillbirth have been seen 
during epidemics.9,10
Intermittent preventive treatment of malaria in pregnancy (IPTp) with sulfadoxine/
pyrimethamine (SP) as well as insecticide-treated nets (ITN) are recommended methods of 
malaria control in pregnancy in areas of stable transmission in sub-Saharan Africa.11 LBW 
and maternal anaemia are key indicators for monitoring malaria intervention programmes in 
pregnancy,12 and have been shown to significantly improve with use of either IPTp3,13,14 or 
ITNs.15 Less information exists on the efficacy of both interventions together.16-18 Most 
trials have been conducted in areas of high malaria transmission, with very few studies 
undertaken in areas of low, unstable or highly seasonal transmission,8,19 and thus no specific 
guidance on malaria control during pregnancy is currently available for areas of low or 
unstable transmission in Africa.
A randomized trial was undertaken in the highlands of southwestern Uganda to evaluate the 
effect of IPTp and ITNs (used alone or in combination with IPTp) on maternal anaemia and 
LBW as well as to investigate the comparative cost-effectiveness of the three interventions 
in an area of low and unstable malaria transmission. This paper reports the effect of the 
interventions on maternal and foetal outcomes.
Ndyomugyenyi et al. Page 2
Trans R Soc Trop Med Hyg. Author manuscript; available in PMC 2014 October 22.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Materials and Methods
Study site and population
The study was conducted in Kabale district, a highland district, situated in southwestern 
Uganda, lying at an altitude between 1,219m and 2,347m above sea level. The majority of 
the district lies within the malaria epidemic-prone zone. According to the 2002 census, the 
population of Kabale district was 461,785 people, with a population density of 290 
persons/km2. The temperature is fairly constant throughout the year, with maximum daily 
temperatures of 23.2 - 24.4 °C, dropping to a minimum of 9.8 - 12.6°C at night. Rainfall is 
seasonally bimodal, averaging between 1,000 and 1,480 mm per annum. Malaria 
transmission is low and unstable, with the entomological inoculation rate previously 
estimated at 0.41 infective bites/person/year.20 Malaria transmission occurs most years, 
usually following the seasonal pattern of rainfall which peaks during April-June and 
September-November. The intensity and extent of transmission varies from year to year 
resulting in periodic epidemics which can be associated with high morbidity and mortality 
rates, and an increased risk of stillbirths.10 Pregnant women were recruited at 10 rural health 
units, serving the 47 parishes included in the study area, covering approximately one-half 
the district. Each health unit was staffed by a qualified midwife.
Study design
An individually-randomized placebo-controlled three-arm intervention trial was conducted 
to examine the efficacy of three preventive approaches in improving pregnancy outcomes. 
The effect of using (i) ITNs + placebo; and (ii) ITNs in combination with IPTp (dual 
intervention) were compared to (iii) use of IPTp alone (current practice comparator). For 
ethical reasons, there was no placebo arm; all women received one or more preventive 
interventions against malaria. The primary trial endpoints were the prevalence of LBW and 
maternal anaemia. An independent data safety monitoring board oversaw implementation of 
the trial and approved the analytical plan prior to analysis. Analysis for all primary 
endpoints was completed before the data were unmasked.
Enrolment and administration of the interventions
Community sensitisation was carried out to inform local communities of the risks of malaria 
in pregnancy, the benefits of early attendance to antenatal care (ANC), and the research that 
would be taking place in local clinics. Women of all parities whose pregnancies were < 27 
weeks gestation at first antenatal presentation were eligible for inclusion in the study. After 
written informed consent was obtained at first ANC attendance, women were individually 
assigned to one of the three study groups, using a computer-generated random number list 
with individual sealed envelopes (arranged in blocks of 12). Tablets of SP or placebo, 
identical in shape and colour, were obtained from Kampala Pharmaceutical Industries 
(Kampala, Uganda) and were stored in tins labeled only with a single identification letter 
corresponding to the study group. Solubility and drug content were confirmed using high 
performance liquid chromatography (HPLC). All study participants, health staff and 
researchers were blind to drug assignment (SP or placebo), but not to ITN use.
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The first treatment dose of SP (or placebo) was given once gestational age was ≥ 16 weeks 
and women reported foetal movement, or at enrolment if later. Assessment of gestational 
age was made by bimanual palpation and use of a fundal height tape to estimate fundal 
height at each antenatal visit. A pregnancy test was administered when the fundus was not 
palpable. Women with a confirmed pregnancy of < 16 weeks gestation were enrolled into 
the study and were advised to return for their first treatment dose of SP as soon as they 
sensed any foetal movement. A second treatment dose was given in the third trimester of 
pregnancy (between gestational weeks 28 and 34). All doses of IPTp were given under 
conditions of directly observed treatment. Home visitors reminded women when to re-attend 
for their second dose of IPTp, as well as at week 36 for haemoglobin (Hb) assessment and 
delivery advice. Women were also encouraged to present to the health unit in the event of 
any fever or other illness during pregnancy. Study cards with a unique identification number 
facilitated identification at every contact throughout the study.
Women who were randomised to receive an ITN [(study arms (i) and (ii)] received a treated 
net, and instructions on its use at the time of enrolment. Nets were pre-treated with KO-tab® 
(deltamethrin) by study staff. Women were visited at home shortly after enrolment to advise 
them on use and care of the net and verify that it was being used. Women in the current 
practice arm (iii) received an ITN after delivery.
Exclusion criteria
Women presenting with gestational age >26 weeks at first antenatal booking, those who 
were not resident in the study area, visitors and temporary residents were not eligible for 
enrolment. Other exclusion criteria included history of adverse drug reaction, or severe 
disease (such as hepatitis, jaundice, tuberculosis, obvious AIDS symptoms). Women were 
screened for anaemia at first antenatal booking; women with severe anaemia (Hb<7.0g/dl) 
were treated with a full course of iron and folic acid, and excluded from enrolment. All 
women excluded from the trial received IPTp with SP, as per current practice.
Maternal and infant health outcomes
Primary maternal health outcomes were prevalence of maternal anaemia (Hb <11.0g/dl), and 
mean Hb concentration at 36-40 weeks gestation. Hb concentration was measured using a 
HemoCue photometer (HemoCue Corp., Angelholm, Sweden). Blood films were also 
prepared for malaria parasite examination at last ANC visit between 36-40 weeks gestation, 
as well as in any episode of suspected febrile illness presenting to the health unit. Peripheral 
and placental blood smears were taken at delivery. Blood slides were stained with Giemsa 
and all were read independently by two research technicians and were only declared 
negative after 200 high-power fields had been examined. In the case of discrepant slides, the 
results of microscopy performed by a senior technician and trainer with many years 
experience of reading malaria slides was considered definitive. A clinical episode of malaria 
was defined as a presence of malaria parasites in a peripheral blood film in a woman 
presenting with a history of fever and/or an axillary temperature ≥ 37.5°C. Evidence of any 
maternal malaria infection was defined as the presence of asexual parasites of any density 
detected in at least one maternal blood film taken at the end of pregnancy, including 
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peripheral blood films taken at antenatal attendance between 36-40 weeks gestation, 
peripheral blood films taken at delivery, and blood films prepared from the placenta.
Primary infant health outcomes were prevalence of LBW (< 2500g) and mean birth weight. 
Other infant outcomes included numbers of abortions, stillbirths, premature births and 
neonatal deaths. Newborns were weighed on a digital scale, accurate to the nearest 10g. A 
blood sample was taken from the heel of infants at birth to measure neonatal Hb and prepare 
a blood film for malaria parasite examination. Midwives estimated gestational age at birth 
using the Ballard external criteria21,22 for all babies delivered at a health unit. Babies that 
were not delivered at a health unit were visited and weighed at home by a home visitor, and 
a blood film was prepared from mother, baby and placenta where possible. Mother and 
newborn were visited every week for the first 28 days to capture data on early and late 
neonatal mortality and/or maternal deaths.
Sample size calculations
Sample size was determined to detect a reduction in frequency of maternal anaemia at week 
36, LBW and stillbirths. Data from an earlier study in Kenya,16 which showed an additive 
effect of ITNs on anaemia and an improvement in protective efficacy (PE) from 50% (IPTp 
alone) to 60% (IPTp+ITN), were used to inform sample size calculations. The additive 
effect was expected to be greater in a low transmission setting, and we further considered 
that an improvement in PE of <20% (increase in protective efficacy from 50% to 70%) to be 
of negligible public health importance to detect. Assuming the prevalence of maternal 
anaemia in the absence of intervention is 25%,19 the minimum sample size needed to detect 
a difference, assuming the prevalence of maternal anaemia after the intervention was 12.5% 
in the IPTp alone arm (PE=50%) and 7.5% in the dual intervention arm (IPTp+ITN; 
PE=70%), was 603 women in each arm (significance level of 0.05 and power of 0.80). The 
other study outcomes (frequency of LBW and stillbirths) are less common10 and required a 
larger sample size to detect a difference in PE between the intervention groups. A minimum 
sample size of 1604 women per arm was required to detect a difference if the prevalence of 
LBW after the intervention was 5% in the IPTp alone arm (PE=50%) and 3% in the dual 
intervention arm (PE=70%).
Data analysis
Data were analysed according to modified intention-to-treat, whereby study outcomes in all 
women were included regardless of whether they had received the intervention and the 
intended number of doses. Women who were found to have enrolled at more than one site, 
to be non-resident within the study area (enrollment errors) or to have attended ANC outside 
the study area were regarded as protocol violations and were removed from the dataset 
before analysis. Principal components analysis was used to generate an index of 
socioeconomic status based on ownership of household and agricultural assets ascertained 
during household surveys, and used to categorise women to wealth quintiles.23 The location 
of each household was mapped using a handheld Geko™ 201 global positioning system 
(Garmin, Olathe, Kansas, USA), which has an accuracy of ±15m, and used to estimate the 
elevation of residence using a digital elevation model for the study area.24 Birth weights, 
which were measured 1-7 days after birth, were adjusted to account for the expected changes 
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in weight within a few days of birth25 using an estimate of daily mean weight change in a 
separate cohort of 100 non-study babies born in Kabale and weighed every day for the first 7 
days after birth. Study babies weighed >7 days after birth were coded as missing data and 
were excluded from analysis of birth weight. Multiple births (twins) were excluded from all 
analyses of foetal outcomes, including LBW and preterm births.
Summary statistics were used initially to describe the study sample. These included number 
in each arm of the study and follow-up status, e.g. number of non-missing endpoint 
measurements, information on missing data and characteristics of women in each 
intervention arm at enrollment using information from antenatal booking record and 
household questionnaire. Data were examined to identify any imbalances in covariates and 
potential confounders between the three study arms (randomisation failure). Pre-specified 
covariates to consider in an adjusted analysis included recognised risk factors for LBW and 
maternal anaemia, such as maternal age, parity, education and nutritional status; as well as 
factors associated with exposure to malaria, including altitude of residence and use of an 
ITN outside the trial protocol.
The means of birth weight and Hb concentration in the three treatment arms were compared 
by Student’s t-test and one-way ANOVA. Proportions were compared using Chi square and 
P-values < 0.05 were considered significant in all tests. In highland area, altitudinal decrease 
in ambient temperature is the primary limiting factor for malaria transmission, such that the 
altitudinal zone between 1500m and 1750m probably represents the fringes of stable 
transmission in Uganda.26 Thus, in addition to the main analysis of pregnancy endpoints, 
pre-specified exploratory analyses were undertaken to include data only from women living 
below 1800m, at highest likelihood of malaria exposure during pregnancy. Data were 
analysed using Stata 10 (StataCorp LP, College Station, Texas, USA).
Results
Overall, 5775 pregnant women were recruited into the study at their first ANC visit between 
2004 and 2007, with 1916, 1931 and 1928 randomised to the IPTp, ITN and dual 
intervention (IPTp+ITN) groups, respectively (Figure 1). Retention rates were similar across 
the three intervention groups, with >90% of women evaluated at delivery. The main reasons 
for loss to follow-up were outmigration (51%); non-residence (19%) or ANC attendance 
outside the study area (10%). Twelve women withdrew consent and one woman experienced 
an adverse event after IPTp and was withdrawn from the study. Two women died before 
delivery, after 28 weeks and 36 weeks gestation in the IPTp and dual intervention groups, 
respectively. Verbal autopsy interviews revealed a history of general weakness and history 
of weight loss. Clinical reviews were inconclusive.
Baseline characteristics of the study women were comparable with respect to age, parity, Hb 
concentration at enrolment, nutritional and socioeconomic parameters, and altitude of 
residence (Table 1). The mean age of women enrolled in the study was 25.7 years (range 
15-47 years), with 20% of women being primigravidae. Mean Hb concentration at 
enrolment was 12.16 g/dl. Altitude of residence ranged between 1367m and 2352m above 
sea level, with approximately one-half the study population living below 1800m in the 
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altitudinal zone classified as ‘highland-fringe’ where the risk of malaria transmission is 
highest.26
The three groups were also comparable with respect to mean gestational age at enrolment, 
and number of treatments received. The mean gestational age at recruitment was 18 weeks 
in all study groups (P=0.666), with over one-half the women presenting for antenatal 
booking before 20 weeks gestation. As a result, over 75% of the women received two or 
more doses of SP during pregnancy: (79.1%, 76.3% and 78.0% in the IPTp, ITN and dual 
intervention groups respectively; χ2 =4.36, df 2, P=0.113), amongst whom 16.2%, 15.2% 
and 14.4% of women, respectively, received three doses. Over 97% of women randomised 
to receive an ITN at enrolment used the net during pregnancy. In contrast, bed net use in the 
IPTp group was only 6%.
Hb was measured during ANC re-attendance visits at 36-40 weeks gestation and/or 
immediately prior to delivery. Owing to low antenatal re-attendance rates and high numbers 
of home births, Hb at 36-40 weeks gestation was only recorded for approximately 50% of 
the women (Figure 1). Completeness of maternal Hb recording was similar in all 
intervention groups (χ2 =2.31, df 2, P=0.315). However, recording of Hb differed between 
socioeconomic groups, ranging between 49 and 58%, with data being more complete for the 
least poor quintiles (χ2 =20.42, df 4, P<0.001). Birth weights were recorded within 7 days 
for over 92% of live singleton births in all three intervention groups (χ2 =1.70, df 2, 
P=0.427).
Pregnancy outcomes
The majority of women (70%) delivered in the village and only 30% delivered at a health 
unit. Six women died during or shortly after delivery due to obstetric causes (3), 
complications following a spontaneous abortion (1) and suicide due to puerperal psychosis 
(1); the cause of death was undetermined in one woman with a history of fever. Most 
women delivered successfully (>95% live births), though 2% of the pregnancies ended in 
spontaneous abortion and 2% of babies were stillborn. Pregnancy outcomes were similar 
across the three intervention groups (Table 2).
Effect of the interventions on birth weight and other foetal outcomes
Overall, 4713 singleton live births were weighed within 7 days of birth, with an overall 
prevalence of LBW of 6.54%. There was no difference between the three intervention 
groups in either the prevalence of LBW (P=0.802) or mean birth weight (P=0.261) (Table 
3). Birth weight and other study outcomes were strongly associated with altitude of 
residence but not parity (Table 4). Nevertheless, when analysis was restricted to include only 
women living below 1800m, the mean birth weight and prevalence of LBW between the 
three intervention groups remained similar (P=0.501 and P=0.928, respectively) (Table 3).
Likewise, there was no difference between the intervention groups in either the prevalence 
of prematurity (P=0.961) or mean gestational age at birth (P=0.803) in the subgroup of 
babies delivered at a health unit and assessed by a midwife (Table 3). Status at 28 days after 
birth was available for the majority of live births (99.6%), in whom the overall neonatal 
death rate was 20.80 per 1000 live births. The total number of neonatal deaths was similar in 
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the IPTp, ITN and dual intervention groups, with 34, 35 and 38 neonatal deaths recorded, 
respectively (Table 2).
Effect of the interventions on maternal anaemia
Maternal Hb measured at 36 weeks of gestation or before delivery was available for 2814 of 
the 5328 women with delivery outcomes (53%, 51% and 54% of women in the IPTp, ITN 
and dual intervention groups, respectively; P=0.315). There was no difference in the 
prevalence of maternal anaemia (Hb < 11.0 g/dl) between the three intervention groups, 
which ranged from 14% to 16% across the three groups (P=0.234) (Table 5). Severe-to-
moderate anaemia (Hb < 8.0 g/dl) was observed in 21 women (0.75%), comprising 7 in each 
group (χ2 =0.01, df 2, P=0.997). Mean Hb concentration was marginally higher in the dual 
intervention group, being recorded as 12.40, 12.44, and 12.57 g/dl in the IPTp, ITN and dual 
intervention groups, respectively (P=0.040) (Table 5). When analysis was restricted to 
include only women living below 1800m, the differences in mean Hb between the three 
intervention groups remained marginal and did not reach significance (P=0.125) (Table 5).
Effect of the interventions on parasitaemia
Overall, peripheral parasitaemia measured at 36-40 weeks of gestation or at delivery was 
available for 87% of the 5328 women with delivery outcomes (88%, 88% and 86% of 
women in the IPTp, ITN and dual intervention groups, respectively; χ2 =2.71, df 2, 
P=0.258). There was no difference in the prevalence of peripheral parasitaemia between the 
three intervention groups, which ranged between 7% and 9% across the three groups at 
weeks 36-40, and between 10% and 12% at delivery (P=0.219 and P=0.557 respectively) 
(Table 5). Similarly, there was no difference between the intervention groups in the 
prevalence of placental parasitaemia in the subgroup of women who delivered at a health 
unit (P=0.211). An additional 103 slides were taken from study women presenting with 
suspected malaria during pregnancy, of which 28 were found to be parasite-positive. Slide 
positivity in suspected malaria cases did not differ between the three intervention groups 
(P=0.853). The prevalence of congenital parasitaemia was also comparable between the 
three intervention groups (P=0.284).
When slide data were combined, such that the presence of at least one positive placental or 
peripheral blood film taken at the end of pregnancy was considered evidence of a maternal 
infection, the proportion of women with maternal parasitaemia increased to 15.0% overall, 
with 712 of the 4736 women examined having at least one positive slide. Maternal malaria 
infection was strongly associated with altitude of residence in this highland area, decreasing 
from 17.5% among women living below 1700m to 12.3% among women living above 
1900m (P=0.003) (Table 4). Nonetheless, when analysis was restricted to include only 
women living at lower elevations, the proportion of women with any evidence of maternal 
parasitaemia in each of the three intervention groups remained comparable (P=0.354) (Table 
5).
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Discussion
This randomised placebo-controlled trial found no evidence of a difference in effect on 
LBW or maternal anaemia between three malaria preventive strategies during pregnancy 
using either IPTp alone (current practice), ITNs alone or a dual intervention with ITNs used 
in combination with IPTp in an area of low and unstable malaria transmission in Uganda. A 
marginal difference was observed in maternal Hb of 0.2 g/dl, which reached statistical 
significance (P=0.04) but is unlikely to be of clinical significance. No difference was 
observed in the prevalence of maternal anaemia or LBW. Indeed, across all the trial 
endpoints examined the prevalence of maternal and foetal outcomes was remarkably similar 
in all intervention groups. Thus, no evidence was found to indicate that any one preventive 
strategy was superior to prevent the deleterious impact of malaria during pregnancy in areas 
of low and unstable transmission. Moreover, no evidence was observed of any additional 
benefit to providing both IPTp and ITNs through routine antenatal services.
Preventive programmes delivered through ANC frequently face challenges due to late ANC 
attendance and non-compliance,27 which can limit the impact of interventions in pregnancy 
and give rise to a null result. However, in this study the lack of difference between the 
interventions cannot be explained by late or irregular attendance since most women attended 
ANC early due to community sensitisation carried out prior to the start of the study. Mean 
gestational age at enrollment was 18 weeks, with a substantial proportion presenting within 
the first 20 weeks of gestation, early enough for the interventions to have an impact on the 
study outcomes and to maximize the potential benefit of IPTp and ITNs delivered through 
ANC.8,28,29 Neither can poor compliance explain the lack of difference among the 
interventions on study outcomes, since more than 75% of women received two or more 
doses of IPTp in all the intervention groups, and ITN use among women randomised to 
receive a net was > 97%. In contrast, ITN use among women in the current practice group 
was low (< 10%). There are no contemporary data on SP resistance in the study area. The 
most recent study conducted in October 2001 reported 18.5% RI parasitological resistance to 
SP after 14 days of follow-up in malaria patients aged between 2-42 years (no RII or RIII 
resistance),30 but resistance may well have increased in the intervening period. Nevertheless, 
we do not believe that SP resistance compromised the efficacy of IPTp in this study since 
study outcomes in the group of women who only received IPTp with SP were no worse than 
among the two intervention groups in which women used ITNs. Although baseline 
characteristics of women enrolled into the three intervention groups were comparable and 
losses to follow-up were generally low, Hb at weeks 36-40 was only obtained for 50% of the 
enrolled women, with completeness of recording differing according to socioeconomic 
status and thus possibly subject to participation bias. In contrast, data on birth weight was 
recorded for > 90% of women enrolled into the study. Therefore, we can be confident that 
the lack of difference in LBW was not due to randomisation failure, non-compliance, 
suboptimal delivery, differential loss to follow-up or participation bias.
The entomological inoculation rate in the district is low, previously estimated at 0.41 
infective bites/person per year between 1700 and 1960m elevation,20 though with marked 
geographical variation between villages31. A potential consideration is thus whether the 
level of malaria transmission was too low to impact on pregnancy outcomes. This is 
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particularly problematic to evaluate since for ethical reasons there was no placebo arm, and 
all women received a preventive intervention against malaria. The probability of exposure 
will have differed between study subjects since the elevation at which women lived ranged 
between 1367 m and 2352 m above sea level, spanning the altitudinal limits of stable 
transmission in Uganda,26 and elevation of residence was strongly correlated with maternal 
parasitaemia, maternal anaemia and birth weight in this study population. Birth outcomes in 
women who are not exposed to malaria will not be affected by malaria interventions, and 
inclusion of data from these women in the analysis could dilute any observed effects of the 
interventions. Within the study population, the proportion of women with any evidence of 
malaria parasitaemia was found to be 15.0% overall, with the highest levels of infection seen 
in women living below 1700m in whom the proportion with parasitaemia increased to 
17.5%. The difficulties of detecting malaria infection during pregnancy owing to placental 
sequestration are well recognised, and microscopy can significantly underestimate the true 
prevalence of infection in the study population.32 Owing to the high proportion of deliveries 
at home, we were rarely able to obtain placental samples, neither did we undertake placental 
histology. Nevertheless, the levels of parasitaemia observed in our study were not dissimilar 
to the 15% peripheral parasitaemia recorded in an area of moderate perennial transmission in 
Mozambique where the true level of maternal infection during pregnancy was shown to be 
51% according to placental histology.18 Despite the limitations of light microscopy and 
peripheral blood films, we thus believe the parasitological findings from pregnant women in 
Kabale indicate that significant levels of malaria transmission were indeed occurring within 
this highland area. Furthermore, when pre-specified analyses were carried out by altitude, no 
evidence of a difference between the groups was seen even amongst women living at the 
lower altitudes below 1800m, where exposure is higher and any differences in PE between 
the interventions would be more likely to be apparent. Though doubtless not powered to 
detect statistical significance, in all sub-group analyses the prevalence of study endpoints 
were almost identical in all three intervention groups and it seems reasonable to conclude 
that the interventions do not differ in their effect on maternal and foetal outcomes, even in 
those women at greatest risk of malaria. The prevalence of parasitaemia observed was equal 
or greater than that previously reported in other highland areas33-35 and was comparable to 
the median prevalence of peripheral parasitaemia of 13.7% seen in low-transmission African 
settings.8 We thus consider that the background level of transmission in Kabale is probably 
representative of other low-transmission settings in Africa and these trial results are 
generalisable to other settings of low and unstable transmission. It should be noted, 
however, that no epidemic outbreaks occurred in the study area during the period of the trial 
(2004-2008), and the possibility that one strategy might prove to be more efficacious in 
protecting pregnant women from malaria, and the attendant risks of abortion and stillbirth, at 
times of increased transmission in the highlands cannot be ruled out.
These findings are broadly consistent with other published trials. In an individually-
randomised trial conducted in an area of high malaria transmission in western Kenya, IPTp 
and ITNs were both found to be of comparable efficacy, although the combination of IPTp
+ITNs showed a marginally better protective efficacy than either intervention given alone.16 
All three interventions were found more effective in preventing maternal anaemia than case 
management alone. A second trial comparing the use of ITNs with and without the addition 
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of IPTp in an area of moderate malaria transmission in Mozambique found no significant 
difference between the two interventions on the prevalence of LBW and maternal anaemia 
and concluded that ITNs in combination with case management was more appropriate than 
IPTp with SP alone.18 The current trial, conducted in an area of low and unstable 
transmission, similarly did not find any evidence of a difference in efficacy of IPTp and 
ITNs, whether given alone or in combination. We did not evaluate the impact of case 
management or of screening and treatment.
In conclusion, the three preventive strategies evaluated were found to be comparable in 
efficacy in an area of low and unstable transmission. Delivery of ITNs and IPTp through 
ANC was well accepted and compliance with their use was high. Thus, for policy the 
comparative cost of delivering each intervention and the wider public health benefits of ITN 
use may be more relevant considerations than efficacy. Cultural factors such as local 
acceptability of SP or ITNs, which can reduce the effectiveness of an intervention under 
operational conditions, may also be pertinent. The cost of delivery of IPTp with SP was 
found to be lower than the cost of distribution of ITNs through ANC.36 Nevertheless, the 
risk of waning efficacy of SP and current lack of alternative drugs could favour the 
distribution of long-lasting insecticidal nets (LLINs) over the use of IPTp as a preventive 
strategy in areas of low and unstable transmission. This would also reduce the risk of 
adverse effects of co-administration of SP with anti-retroviral drugs or co-trimoxazole in 
pregnant women with HIV/AIDS, and obviate concerns over the exposure to drugs in the 
first trimester.37 In contrast, little or no risk is associated with use of an ITN and they can be 
used within the first trimester, reducing the risk of infection throughout pregnancy. 
Continued use of a LLIN after pregnancy brings additional public health benefits, protecting 
the growing infant through the crucial first year of life and potentially serving to also protect 
the mother from the very first day of a subsequent pregnancy. Antenatal distribution, 
coupled with community-based initiatives, will also help to accelerate progress towards the 
goal of universal ITN coverage. On balance, ITNs provide a number of distinct advantages 
over IPTp and thus may be a more appropriate preventive strategy for malaria control during 
pregnancy in areas of low and unstable transmission.
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Figure 1. 
Trial profile. IPTp: intermittent preventive treatment of malaria during pregnancy; ITN: 
insecticide-treated nets; Hb: haemoglobin
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Table 1
Characteristics at enrollment of the 5328 women followed to terma
Characteristic IPTp (n = 1798) ITN (n = 1778) IPTp+ITN (n = 1752) P-value
Age (years) (mean ± SD) 25.55 ± 5.72 25.78 ± 5.56 25.82 ± 5.72 0.313
Gestational age (weeks) (mean ± SD) 18.21 ± 5.45 18.27 ± 5.70 18.10 ± 5.74 0.666
Haemoglobin (g/dl) (mean ± SD) 12.120 ± 1.522 12.157 ± 1.636 12.232 ± 1.567 0.104
MUAC (cm) (mean ± SD) 26.27 ± 2.41 26.28 ± 2.52 26.33 ± 2.57 0.710
Gestational age (weeks) [n (%)]
 <20 942 (53) 887 (50) 926 (53) 0.169
 20 – 27 849 (47) 883 (50) 819 (47)
Gravidity [n (%)]
 Primigravidae 385 (21) 347 (20) 358 (20)
 Secundigravidae 319 (18) 321 (18) 311 (18) 0.829
 2 -4 prior pregnancies 691 (39) 722 (41) 696 (40)
 ≥ 5 prior pregnancies 400 (22) 386 (22) 386 (22)
Education [n (%)]
 None 263 (15) 228 (13) 228 (13)
 Primary 1353 (76) 1366 (77) 1301 (75) 0.048
 Secondary 172 (10) 180 (10) 213 (12)
Socioeconomic quintile [n (%)]
 1 (least poor) 319 (18) 372 (21) 354 (20)
 2 337 (19) 362 (20) 370 (21)
 3 379 (21) 354 (20) 338 (19) 0.067
 4 382 (21) 322 (18) 345 (20)
 5 (most poor) 364 (20) 361 (20) 332 (19)
MUAC index [n (%)]
 Normal (> 22cm) 1644 (98) 1603 (97) 1572 (97) 0.627
 Underweight (≤ 22cm) 39 (2) 47 (3) 42 (3)
Elevation of residence
 Mean ± SD (m) 1788.28 ± 175.76 1782.06 ± 171.21 1780.80 ± 171.43 0.429
 <1500 m [n (%)] 141 (9) 142 (9) 137 (9)
 1500-1799 m [n (%)] 547 (34) 556 (35) 566 (37) 0.764
 ≥ 1800 m [n (%)] 904 (57) 883 (56) 844 (55)
IPTp: intermittent preventive treatment of malaria during pregnancy; ITN: insecticide-treated net; MUAC: mid-upper arm circumference.
a
The women who died before term (2), were withdrawn from the study (183) or were lost to follow-up (262) are excluded.
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Table 2
Pregnancy outcomes (n=5375)a
IPTp [n (%)] ITN [n (%)] IPTp+ITN [n (%)] P-value
Pregnancy outcomesa
 Spontaneous Abortions 38 (2.1) 34 (1.9) 30 (1.7) 0.686
 Stillbirths 38 (2.1) 34 (1.9) 36 (2.0) 0.910
 Live births 1739 (95.8) 1725 (96.2) 1701 (96.3) 0.748
 Total 1815 1793 1767 -
Neonatal Outcomesa
 Early neonatal deaths (within first 7 days of life) 25 (1.4) 24 (1.4) 36 (2.1) 0.175
 Late neonatal deaths (≥ 8 and <29 days of life) 9 (0.5) 11 (0.6) 2 (0.1) 0.050
 Perinatal deaths (stillbirths + early neonatal deaths) 63 (3.5) 58 (3.2) 72 (4.1) 0.382
Maternal deaths (intra- and post-partum deaths) 1 (<0.1) 2 (0.1) 3 (0.2) 0.590
Congenital abnormalities 6 (0.3) 3 (0.2) 5 (0.3) 0.612
IPTp: intermittent preventive treatment of malaria during pregnancy; ITN: insecticide-treated net.
a
Includes multiple births.
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Table 3
Low birth weight and secondary foetal outcomes according to study group: overall and according to altitude of 
residence and gravidity.
IPTp ITN IPTp+ITN P-value
Low birth weighta (<2500g) [n/N (%)]
 Overall 102 / 1575 (6.48) 99 / 1577 (6.28) 107 / 1561 (6.85) 0.802
  By elevation
   < 1800 m 48 / 630 (7.62) 46 / 626 (7.35) 48 / 605 (7.93) 0.928
   ≥ 1800 m 40 / 739 (5.41) 40 / 738 (5.42) 47 / 730 (6.44) 0.625
  By gravidity
   Primigravidae 16 / 313 (5.11) 18 / 329 (5.47) 27 / 333 (8.11) 0.224
   Secundigravidae 22 / 287 (7.67) 16 / 277 (5.78) 14 / 276 (5.07) 0.417
   2-4 prior pregnancies 40 / 610 (6.56) 37 / 631 (5.86) 44 / 614 (7.17) 0.648
   ≥ 5 prior pregnancies 21 / 347 (6.05) 27 / 325 (8.31) 21 / 315 (6.67) 0.500
Mean ± SD birth weighta (SD)
 Overall 3135.62 ± 430.41 3161.06 ± 452.68 3144.37 ± 444.15 0.261
  By elevation
   < 1800 m 3107.21 ± 416.84 3135.07 ± 455.19 3112.33 ± 465.70 0.501
   ≥ 1800 m 3166.44 ± 443.12 3181.38 ± 445.73 3149.37 ± 426.31 0.376
  By gravidity
   Primigravidae 3162.58 ± 466.00 3174.84 ± 462.62 3124.48 ± 471.38 0.352
   Secundigravidae 3123.04 ± 414.05 3167.02 ± 417.62 3192.50 ± 456.05 0.152
   2-4 prior pregnancies 3134.68 ± 435.38 3149.76 ± 455.88 3130.44 ± 433.80 0.719
   ≥ 5 prior pregnancies 3124.26 ± 401.30 3162.80 ± 467.60 3152.74 ± 425.18 0.485
Secondary foetal outcomesb
 Pre-term birth (<37 weeks) [n/N (%)] 42 / 489 (8.59) 42 / 480 (8.75) 45 / 495 (9.09) 0.961
 Mean ± SD gestational age at birth (weeks) 37.39 ± 0.66 37.37 ± 0.91 37.40 ± 0.73 0.803
 Total no. babies examined for Hb 321 329 332
 Infant Hb at birth (g/dl) (mean ± SD) 19.227 ± 2.566 19.641 ± 2.932 19.532 ± 2.856 0.148
IPTp: intermittent preventive treatment of malaria during pregnancy; ITN: insecticide-treated net; Hb: haemoglobin
aSingleton live births weighed within 7 days of birth, adjusted for number of days after birth and growth
bGestational age at birth and neonatal Hb was only available for singleton live births delivered at a health unit.
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Table 4
Effect of gravidity and elevation of residence on study outcomes
Any malaria infectiona 
[n/N (%)]
Maternal anaemia [n/N 
(%)]
Low birth weight [n/N 
(%)] Mean ± SD birth weight
Elevation
 <1700 m 175 / 999 (17.52) 172 / 746 (23.06) 88 / 1028 (8.56) 3085.14 ± 446.64
 1700-1799 m 151 / 861 (17.54) 40 / 490 (8.16) 54 / 833 (6.48) 3159.10 ± 442.17
 1800-1899 m 205 / 1439 (14.25) 88 / 793 (11.10) 80 / 1421 (5.65) 3180.73 ± 435.94
 ≥ 1900 m 103 / 835 (12.34) 59 / 443 (13.32) 47 / 786 (5.98) 3138.77 ± 442.11
 P-value 0.003 <0.001 0.028 <0.001
Gravidity
 Primigravidae 141 / 982 (14.36) 80 / 613 (13.05) 61 / 975 (6.26) 3153.71 ± 466.73
 Secundigravidae 133 / 856 (15.54) 74 / 501 (14.77) 52 / 840 (6.19) 3160.37 ± 429.90
 2-4 prior pregnancies 277 / 1858 (14.91) 168 / 1074 (15.64) 121 / 1855 (6.52) 3138.41 ± 441.79
 ≥ 5 prior pregnancies 159 / 1026 (15.50) 91 / 618 (14.72) 69 / 987 (6.99) 3146.04 ± 431.52
 P-value 0.870 0.554 0.892 0.639
a
Presence of malaria parasites in one or more blood films taken at the end of pregnancy, including peripheral blood films taken at antenatal 
attendance between 36-40 weeks gestation, peripheral blood films taken at delivery and blood films prepared from the placenta.
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Table 5
Maternal anaemia and parasitological outcomes by study groupa: Overall effect and categorized by altitude of 
residence.
IPTp ITN IPTp+ITN P-value
Maternal anaemia (< 11.0 g/dl) [n/N (%)]
 Overall 135 / 953 (14.17) 149 / 915 (16.28) 129 / 946 (13.64) 0.234
 Elevation
  < 1800 m 73 / 434 (16.82) 80 / 402 (19.90) 59 / 400 (14.75) 0.150
  ≥ 1800 m 48 / 424 (11.32) 53 / 400 (13.25) 46 / 412 (11.17) 0.593
Mean maternal haemoglobin (g/dl) (mean ± SD)
 Overall 12.395 ± 1.471 12.441 ± 1.561 12.567 ± 1.557 0.040
 Elevation
  < 1800 m 12.289 ± 1.403 12.252 ± 1.602 12.454 ± 1.492 0.125
  ≥ 1800 m 12.501 ± 1.467 12.574 ± 1.487 12.725 ± 1.505 0.085
Parasitological outcomes [n/N (%)]
 Peripheral parasitaemia at weeks 36-40 83 / 883 (9.40) 60 / 841 (7.13) 75 / 853 (8.79) 0.219
 Peripheral parasitaemia at delivery 157 / 1431 (10.97) 148 / 1431 (10.34) 160 / 1377 (11.62) 0.557
 Placental parasitaemia 28 / 651 (4.30) 16 / 622 (2.57) 19 / 613 (3.10) 0.211
 No. of suspected malaria cases 38 30 35
 Slide-positive clinical malaria 11 / 38 (28.95) 7 / 30 (23.33) 10 / 35 (28.57) 0.853
Any malaria infection at end of pregnancyb [n/N (%)]
 Overall 254 / 1606 (15.82) 212 / 1580 (13.42) 246 / 1550 (15.87) 0.088
 Elevation
  < 1800 m 122 / 648 (18.83) 95 / 602 (15.78) 109 / 610 (17.87) 0.354
  ≥ 1800 m 105 / 779 (13.48) 98 / 779 (12.58) 105 / 716 (14.66) 0.499
Congenital parasitaemia 46 / 1351 (3.40) 45 / 1331 (3.38) 32 / 1298 (2.47) 0.284
IPTp: intermittent preventive treatment of malaria during pregnancy; ITN: insecticide-treated net.
aOutcome data were not available for all womenowing to a lack of re-attendance late in pregnancy and delivery at home. Blood films were 
prepared from all women and babies delivering at a health unit and, where possible, those born at home.
b
Presence of malaria parasites in one or more blood films taken at the end of pregnancy, including peripheral blood films taken at antenatal 
attendance between 36-40 weeks gestation, peripheral blood films taken at delivery and blood films prepared from the placenta.
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